MX2023012766A - Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores. - Google Patents
Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores.Info
- Publication number
- MX2023012766A MX2023012766A MX2023012766A MX2023012766A MX2023012766A MX 2023012766 A MX2023012766 A MX 2023012766A MX 2023012766 A MX2023012766 A MX 2023012766A MX 2023012766 A MX2023012766 A MX 2023012766A MX 2023012766 A MX2023012766 A MX 2023012766A
- Authority
- MX
- Mexico
- Prior art keywords
- tumors
- immune cells
- cells infiltration
- allowing immune
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2021/050572 WO2022226623A1 (en) | 2021-04-27 | 2021-04-27 | Method for allowing immune cells infiltration in tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012766A true MX2023012766A (es) | 2024-02-23 |
Family
ID=83846453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012766A MX2023012766A (es) | 2021-04-27 | 2021-04-27 | Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores. |
| MX2023012768A MX2023012768A (es) | 2021-04-27 | 2022-04-26 | Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012768A MX2023012768A (es) | 2021-04-27 | 2022-04-26 | Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240199758A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4329801A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2024516416A (cg-RX-API-DMAC10.html) |
| KR (2) | KR20240014052A (cg-RX-API-DMAC10.html) |
| CN (2) | CN117479955A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2021442702A1 (cg-RX-API-DMAC10.html) |
| CA (2) | CA3173786A1 (cg-RX-API-DMAC10.html) |
| IL (2) | IL307954A (cg-RX-API-DMAC10.html) |
| MX (2) | MX2023012766A (cg-RX-API-DMAC10.html) |
| WO (2) | WO2022226623A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4329801A4 (en) * | 2021-04-27 | 2025-05-14 | Alethia Biotherapeutics Inc. | Method for allowing immune cells infiltration in tumors |
| EP4475885A4 (en) * | 2022-02-07 | 2026-02-18 | Alethia Biotherapeutics Ulc | POLYTHERAPY INTENDED FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| CN118914553B (zh) * | 2024-07-22 | 2025-03-18 | 西安医学院第一附属医院 | 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1882A (en) | 1872-12-11 | Angus. Campbell | A towel hanger | |
| ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
| CA2928846A1 (en) * | 2009-11-24 | 2011-06-03 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| CA2862739A1 (en) * | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| EP4329801A4 (en) * | 2021-04-27 | 2025-05-14 | Alethia Biotherapeutics Inc. | Method for allowing immune cells infiltration in tumors |
-
2021
- 2021-04-27 EP EP21938161.3A patent/EP4329801A4/en active Pending
- 2021-04-27 JP JP2023566662A patent/JP2024516416A/ja active Pending
- 2021-04-27 WO PCT/CA2021/050572 patent/WO2022226623A1/en not_active Ceased
- 2021-04-27 CN CN202180099369.0A patent/CN117479955A/zh active Pending
- 2021-04-27 CA CA3173786A patent/CA3173786A1/en active Pending
- 2021-04-27 KR KR1020237040576A patent/KR20240014052A/ko active Pending
- 2021-04-27 AU AU2021442702A patent/AU2021442702A1/en active Pending
- 2021-04-27 US US18/287,327 patent/US20240199758A1/en active Pending
- 2021-04-27 MX MX2023012766A patent/MX2023012766A/es unknown
- 2021-04-27 IL IL307954A patent/IL307954A/en unknown
-
2022
- 2022-04-26 MX MX2023012768A patent/MX2023012768A/es unknown
- 2022-04-26 WO PCT/CA2022/050632 patent/WO2022226637A1/en not_active Ceased
- 2022-04-26 JP JP2023565954A patent/JP2024516818A/ja active Pending
- 2022-04-26 CN CN202280042256.1A patent/CN117479956A/zh active Pending
- 2022-04-26 KR KR1020237040565A patent/KR20240013743A/ko active Pending
- 2022-04-26 CA CA3173797A patent/CA3173797A1/en active Pending
- 2022-04-26 EP EP22794137.4A patent/EP4329802A4/en active Pending
- 2022-04-26 IL IL307961A patent/IL307961A/en unknown
- 2022-04-26 US US18/287,331 patent/US20240317884A1/en active Pending
- 2022-04-26 AU AU2022266854A patent/AU2022266854A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240013743A (ko) | 2024-01-30 |
| IL307961A (en) | 2023-12-01 |
| WO2022226637A1 (en) | 2022-11-03 |
| KR20240014052A (ko) | 2024-01-31 |
| CA3173786A1 (en) | 2022-10-27 |
| CN117479956A (zh) | 2024-01-30 |
| AU2022266854A1 (en) | 2023-11-30 |
| EP4329801A1 (en) | 2024-03-06 |
| JP2024516416A (ja) | 2024-04-15 |
| EP4329801A4 (en) | 2025-05-14 |
| WO2022226623A1 (en) | 2022-11-03 |
| AU2021442702A1 (en) | 2023-11-30 |
| EP4329802A1 (en) | 2024-03-06 |
| CN117479955A (zh) | 2024-01-30 |
| MX2023012768A (es) | 2023-11-13 |
| US20240317884A1 (en) | 2024-09-26 |
| US20240199758A1 (en) | 2024-06-20 |
| JP2024516818A (ja) | 2024-04-17 |
| CA3173797A1 (en) | 2023-10-05 |
| AU2022266854A9 (en) | 2023-12-07 |
| EP4329802A4 (en) | 2025-09-03 |
| IL307954A (en) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013523A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t | |
| BR112021018442A2 (pt) | Anticorpos multiespecíficos egfr x cd28 | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| BR112012022802A2 (pt) | uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama | |
| BR112022026236A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr | |
| MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
| WO2022026360A3 (en) | Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use | |
| BR112021008549A2 (pt) | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor | |
| MX2020001856A (es) | Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo. | |
| MX2023012768A (es) | Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores. | |
| MX2023014069A (es) | Composiciones y métodos para el tratamiento del cáncer de próstata. | |
| WO2022150732A3 (en) | Chimeric receptor therapy | |
| EP4378530A3 (en) | Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| PH12022551078A1 (en) | Combination therapy to treat brain cancer | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| EA201991870A1 (ru) | Лечение рака мочевого пузыря с помощью антитела к pd-l1 | |
| BRPI0511187A (pt) | método para tratar cáncer em um indivìduo | |
| MX2025008525A (es) | Métodos y composiciones para la terapia combinada | |
| WO2020226986A3 (en) | Methods of treating cancer with an anti-pd-l1 antibody | |
| WO2021011844A3 (en) | Combination cancer therapy agents and methods | |
| WO2022238963A3 (en) | Genetically engineered immune cells targeting cd70 for use in treating solid tumors | |
| MX2022014886A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino. | |
| AU2021334165A8 (en) | Method of treatment of patients having reduced sensitivity to a BCL-2 inhibitor | |
| MX2023001233A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2. |